Aprea Therapeutics secured $3.1 million through a private placement with new and existing healthcare investors.
The company's cash runway is extended into Q1 2027, expecting inflection points in clinical programs.
Proceeds from the private placement to fund general corporate purposes and research and development expenses.
Private Placement Details
2,623,023 shares of common stock sold with warrants at an offering price of $1.165 per share.
Use of Proceeds
Funds allocated for general corporate purposes and research and development, expected to sustain operations until 2027.
Closing Date
Offering expected to close on or about December 10, 2025, facilitated by Maxim Group LLC.
- The private placement is crucial for extending the company's cash flow, ensuring operational stability.
- Funds will enable continued research and development, potentially leading to clinical program advancements.
Aprea Therapeutics' successful private placement ensures financial stability and reinforces commitment to innovative cancer treatments.